GCL1815 reduces cold symptoms Induces Two Types of Dendritic Cell Activation and Effectively Suppresses Onset of the Common Cold: A Randomized, Double-Blind, Placebo-Controlled Trial.
We looked into how GCL1815, a type of lactic acid bacterium, might aid in preventing the common cold. In our randomized, double-blind study with 200 participants, we found that those who took GCL1815 capsules for eight weeks had significantly lower symptoms of colds, like fatigue and nasal congestion, compared to those on placebo. We also observed key immune responses related to dendritic cell activation that were notably more enhanced in participants taking GCL1815. This suggests that GCL1815 is promising in boosting the body’s defenses against the cold.
Read More
Lactobacillus impact on immunitySupplementation with heat-sterilized Lactobacillus crispatus strain KT-11 stimulates the T cell-related immune function of healthy Japanese adults: A pilot randomized, placebo-controlled, double-blind, parallel-group study.
We conducted a pilot study to explore the effects of heat-sterilized Lactobacillus crispatus strain KT-11 on immune function in healthy adults. Over four weeks, 22 participants took either KT-11 or a placebo. We observed that those taking KT-11 had higher counts of certain immune cells and reported fewer cold-like symptoms, particularly fatigue. However, there were no significant increases in antibodies related to SARS-CoV-2. This indicates potential benefits of KT-11 for immune activity, suggesting further studies on its effectiveness are warranted.
Read More